Almac Group announces £11m investment to expand global analytical services

Almac Group, the global contract development and manufacturing organisation (CDMO), has today announced an £11m investment and the creation of over 100 new jobs to expand global analytical services capabilities. 

Over the past 18 months, Almac Sciences, which provides development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API), and Almac Pharma Services, which specialises in pharmaceutical drug product development, manufacture and commercial services, have jointly made this significant investment to expand their existing analytical laboratories, technology and resource to meet ongoing global demand.